Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Peptide-based trial data, complex milestone payments, and frequent equity raises make Altimmune Inc’s disclosures tough to navigate. If you have ever searched “Altimmune SEC filings explained simply,” you already know the challenge: hundreds of pages packed with technical language and biotech accounting rules.
Stock Titan solves this problem with AI-powered summaries that turn every Altimmune quarterly earnings report 10-Q filing and Altimmune annual report 10-K simplified into plain-English insights. Our platform streams Altimmune Form 4 insider transactions real-time, flags cash-burn trends, and links each note in seconds—no more digging for footnotes on clinical trial spend. Need to monitor an unexpected disclosure? Our engine pushes alerts the moment an Altimmune 8-K material events explained notice hits EDGAR.
Whether you are comparing R&D expense trajectories or tracking Altimmune executive stock transactions Form 4, you will find every document in one place. Investors often ask, “Where can I review Altimmune proxy statement executive compensation details?” or “How should I interpret an Altimmune insider trading Form 4 transactions spike before data readouts?” Our expert commentary answers these questions and more, providing Altimmune earnings report filing analysis that ties revenue forecasts to trial timelines. By understanding Altimmune SEC documents with AI, you can evaluate dilution risk, anticipate capital needs, and follow pemvidutide’s clinical progress—all without wading through dense biotech jargon.
Altimmune (Nasdaq: ALT) filed an 8-K reporting positive topline data from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
- MASH resolution without fibrosis worsening reached 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001).
- Histologic fibrosis improvement (31.8%/34.5% vs 25.9% placebo) was not significant, but AI analysis showed ≥60% fibrosis reduction in 30.6% at 1.8 mg vs 8.2% placebo (p<0.001).
- Mean weight loss 5.0%/6.2% vs 1.0% placebo (p<0.001); liver fat fell 58.0%/62.8% vs 16.2%.
- Safety: 0–1.2% AE-related discontinuations; no drug-related SAEs.
Slides (Ex 99.2) accompany a call on 26 Jun 2025. Forward-looking statements cite regulatory, trial and funding risks.
FAQ
What is the current stock price of Altimmune (ALT)?
What is the market cap of Altimmune (ALT)?
What is the primary focus of Altimmune Inc?
What is pemvidutide and how does it work?
How is Altimmune positioned within the clinical-stage biopharmaceutical sector?
What clinical development activities is Altimmune currently undertaking?
How does Altimmune’s dual receptor agonist differ from traditional treatments?
What are some challenges that Altimmune might face in its development process?
Who are the typical competitors in the field of metabolic disease therapeutics?
